C. De Gislain

644 total citations
15 papers, 441 citations indexed

About

C. De Gislain is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C. De Gislain has authored 15 papers receiving a total of 441 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C. De Gislain's work include Chemotherapy-induced organ toxicity mitigation (4 papers), Brain Metastases and Treatment (2 papers) and Endometrial and Cervical Cancer Treatments (2 papers). C. De Gislain is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (4 papers), Brain Metastases and Treatment (2 papers) and Endometrial and Cervical Cancer Treatments (2 papers). C. De Gislain collaborates with scholars based in France, Germany and Tunisia. C. De Gislain's co-authors include B. Cutuli, B. De Lafontan, J Berlié, C. Marchal, J Guerrin, Érick Gamelin, F. Campana, Michel Héry, Y Graïc and M Lacroze and has published in prestigious journals such as International Journal of Cancer, European Journal of Cancer and Breast Cancer Research and Treatment.

In The Last Decade

C. De Gislain

14 papers receiving 425 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. De Gislain France	9	192	176	141	137	116	15	441
J.T. Soper United States	9	46 0.2×	47 0.3×	17 0.1×	165 1.2×	112 1.0×	14	417
Monica Zuradelli Italy	11	133 0.7×	89 0.5×	54 0.4×	186 1.4×	87 0.8×	34	378
Malek M. Safa United States	9	108 0.6×	131 0.7×	94 0.7×	125 0.9×	37 0.3×	26	357
Gaetano Saggio Italy	13	42 0.2×	144 0.8×	13 0.1×	210 1.5×	70 0.6×	28	468
Valeria Forestieri Italy	10	78 0.4×	49 0.3×	41 0.3×	387 2.8×	101 0.9×	24	536
Andre M. Kallab United States	9	54 0.3×	20 0.1×	15 0.1×	92 0.7×	67 0.6×	17	285
Brian M.J. Cantwell United Kingdom	12	32 0.2×	15 0.1×	22 0.2×	236 1.7×	83 0.7×	21	369
Karl Verpoort Germany	7	51 0.3×	65 0.4×	9 0.1×	222 1.6×	53 0.5×	10	370
M F Brady United States	5	30 0.2×	62 0.4×	6 0.0×	184 1.3×	55 0.5×	8	600
JoAnn C. Kelly United States	11	37 0.2×	51 0.3×	4 0.0×	192 1.4×	105 0.9×	17	466

Countries citing papers authored by C. De Gislain

Since Specialization

Citations

This map shows the geographic impact of C. De Gislain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. De Gislain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. De Gislain more than expected).

Fields of papers citing papers by C. De Gislain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. De Gislain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. De Gislain. The network helps show where C. De Gislain may publish in the future.

Co-authorship network of co-authors of C. De Gislain

This figure shows the co-authorship network connecting the top 25 collaborators of C. De Gislain. A scholar is included among the top collaborators of C. De Gislain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. De Gislain. C. De Gislain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Mornex, F., L. Thomas, Peter Mohr, et al.. (2003). A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Research. 13(1). 97–103. 104 indexed citations

Mornex, F., L. Thomas, Peter Mohr, et al.. (2003). Essai de phase III randomisé comparant la fotémustine seule ou associée à une irradiation encéphalique dans les métastases cérébrales de mélanome†. Cancer/Radiothérapie. 7(1). 1–8. 20 indexed citations

Riedinger, Jean‐Marc, N. Eche, J P Basuyau, et al.. (2002). [Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles].. PubMed. 60(2). 183–91. 1 indexed citations

Cutuli, B., Anne de la Rochefordière, Nicolás Isambert, et al.. (2000). [Leukemia and pre-leukemic conditions occurring after treatment of breast cancer].. PubMed. 29(3). 135–8. 6 indexed citations

Mignotte, H., Christine Lasset, Valérie Bonadona, et al.. (1998). Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. International Journal of Cancer. 76(3). 325–330. 80 indexed citations

Lesur, A., É. Luporsi, J F Rodier, et al.. (1997). Endometrial carcinoma (EC) in women with breast cancer (BC). European Journal of Cancer. 33. S205–S205.

Cutuli, B., M Lacroze, Jean-Marie Dilhuydy, et al.. (1995). Male breast cancer: Results of the treatments and prognostic factors in 397 cases. European Journal of Cancer. 31(12). 1960–1964. 164 indexed citations

Coudert, Bruno, C. De Gislain, F. Mayer, et al.. (1995). 966 Feasibility of 5-FU therapeutic monitoring. European Journal of Cancer. 31. S201–S201. 2 indexed citations

Lacour, J.‐P., A. Laplanche, T. Delozier, et al.. (1991). Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapyversus chemotherapy with CMF as adjuvants in operable breast cancer. Breast Cancer Research and Treatment. 19(1). 15–21. 12 indexed citations

10.

Gislain, C. De, Monique Dumas, P D’Athis, et al.. (1991). [Course of blood creatinine during repeated injections of cisplatin. Influence of drug combinations].. PubMed. 45(5). 423–7. 3 indexed citations

11.

Dumas, Monique, et al.. (1990). Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated withcis-diamminedichloroplatinum(II). Cancer Chemotherapy and Pharmacology. 26(4). 278–282. 16 indexed citations

12.

Dumas, Monique, et al.. (1989). Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum. Cancer Chemotherapy and Pharmacology. 23(1). 37–40. 12 indexed citations

13.

Héry, Michel, et al.. (1989). Facteurs de récidive précoce des cancers du sein sans envahissement ganglionnaire axillaire (N. 40(3). 197–202. 1 indexed citations

14.

Gislain, C. De, et al.. (1986). Urinary β2-microglobulin early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide. Cancer Chemotherapy and Pharmacology. 18(3). 276–279. 11 indexed citations

15.

Dumas, Monique, P D’Athis, C. De Gislain, et al.. (1985). Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II).. PubMed. 23(8). 430–3. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact